Silence Therapeutics (LON:SLN) noted today that its licensee Quark Pharmaceutical Inc has reported positive results from a Phase 2 Study to evaluate the efficacy and safety of its QPI-1002 therapy for the prevention of Acute Kidney Injury (AKI).
The AIM-quoted firm - a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need - said Quark has reported that the trial's primary endpoint and multiple secondary endpoints were met in subjects at high risk of AKI following cardiac surgery.
Quark holds a licence to Silence's chemical modification technology. Silence is eligible to receive either approximately 2% royalties from Quark - on QPI-1002 - plus milestones, or 15% of the clinical, regulatory and commercial milestone payments and royalties received by Quark from its Swiss partner Novartis.
Earlier this week, Silence announced that it has bolstered its patent protections in the United States.
The new US patent, ref 9,695,423, provides further protection for Silence's innovative chemical modification technology.
Silence said it believes that the granted patent claims are relevant to third party medicines that are in ongoing clinical trials.
In late afternoon trading, Silence shares rose 5%, or 6.9p higher to 134.75p, taking gains for the week so far to over 25%
-- Adds share price --